期刊
CURRENT DRUG METABOLISM
卷 12, 期 5, 页码 487-497出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138920011795495321
关键词
Adverse drug reactions; Cytochrome P450; drug metabolizing enzymes; pharmacogenetics; pharmacogenomics; single nucleotide polymorphisms
资金
- Pharmacogenetic of Anticancer Agents Research (PAAR) Group, NIH/NIGMS [UO1GM61393]
- University of Chicago [P50 CA125183]
- NIH/NCI [CA136765]
- St. Baldrick's Foundation [43829]
In the field of pharmacogenetics, we currently have a few markers to guide physicians as to the best course of therapy for patients. For the most part, these genetic variants are within a drug metabolizing enzyme that has a large effect on the degree or rate at which a drug is converted to its metabolites. For many drugs, response and toxicity are multi-genic traits and understanding relationships between a patient's genetic variation in drug metabolizing enzymes and the efficacy and/or toxicity of a medication offers the potential to optimize therapies. This review will focus on variants in drug metabolizing enzymes with predictable and relatively large impacts on drug efficacy and/or toxicity; some of these drug/gene variant pairs have impacted drug labels by the United States Food and Drug Administration. The challenges in identifying genetic markers and implementing clinical changes based on known markers will be discussed. In addition, the impact of next generation sequencing in identifying rare variants will be addressed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据